|
|
 |
 |
| Drug Discovery is administered by Osney Media. |
|
|
|
|
 Speakers |
|
|
|
|
Our carefully researched speaker programmes are further enhanced by the opportunity for the delegates and speakers to discuss topics of interest in more detail during panel and round table discussions. This means that the attendees not only benefit from the expertise of the high level speaker panel but also that of the other delegates.
If you have a cutting edge case study or a presentation and would like to join the speaker panel at one of our events, please contact Mike Burden at m.burden@oxfordglobal.co.uk
2010 Advisory Panel Includes:
· Zoran Rankovic, Associate Director Medicinal Chemistry, Schering Plough
· Ted Torphy, Chief Scientific Officer and Head, External Research & Early Development, Johnson & Johnson
· Malcolm Weir, Chief Executive Officer, Heptares Therapeutics
· Jonathan Mason, Chief Scientist, Predictive Technology & Drug Design, Lundbeck Research / Design for Drug Discovery
· Craig Johnstone, Associate Director of Chemistry, Cardiovascular & Gastrointestinal Discovery, AstraZeneca
· Lex Van der Ploeg, Senior Vice President, Integrative Medicine and Translational Science, Abraxis Bioscience
· John Haurum, Chief Scientific Officer, Symphogen A/S
· Per Källblad, Chief Executive Officer, Beactica
· Rod Hubbard, Research Fellow, Vernalis & Structural Biology Lab, University of York
· Patrice Talaga, Director, Chemistry Outsourcing, UCB
· Doriano Fabbro, Head of Kinase Biology, Expertise Platform Kinases, Center for Proteomic Chemistry Novartis
· Johan Luthman, CEO, GeNeuro S.A
· Stevan Djuric, Senior Director, Medicinal Chemistry Technologies, Abbott
· Martin Klumpp, Lab Head Assay Development and Screening, Novartis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salvatore Alesci, Senior Director & Head, Translational Immunology Pfizer
|
|
|
|
Ben Askew, Vice President Research, Head of NCE Technologies, EMD Serono Research Institute
|
|
|
|
Claude Bertrand, Executive Vice President & Chief Scientific Officer, Ipsen
|
|
|
|
Niklas Blomberg, Assocate Director, Computational Chemistry, Astrazeneca
|
|
|
|
Søren Bregenholt, COO, Symphogen
|
|
|
|
Mark Bunnage, Executive Director, Medicinal Chemistry, Pfizer
|
|
|
|
Andrea Cavalli, Senior Scientist, Computational Chemistry, Department of Drug Discovery and Development, Italian Institute of Technology, Genoa
|
|
|
|
Anthony Davies, HCA Research Facility Manager, Trinity College Dublin
|
|
|
|
Andy Davis, Associate Director, Physical & Metabolic Sciences, Astrazeneca
|
|
|
|
John Desjarlais, Vice President, Research, Xencor
|
|
|
|
Jeremy Everett, Vice President, Special Operations, Worldwide Research Centres of Emphasis, Pfizer
|
|
|
|
Stephen Friend, President, CEO and Co-Founder, Sage Bionetworks
|
|
|
|
Rob Hayes, CSO, CENTYREX, a J&J Internal Venture
|
|
|
|
David J. Heard, Group Head Bioinformatics in Investigative Toxicology, Preclinical Safety, Novartis Institutes for Biomedical Research
|
|
|
|
Jutta Heim, Chief Technology Officer, Evolva SA
|
|
|
|
Andrew Hopkins, Research professor of Translational Biology & Chair of Medicinal Informatics Division of Biological Chemistry and Drug Discovery Colege of Life Sciences, University of Dundee
|
|
|
|
Steve Hunt lll, Senior Vice President, Discovery Research, Ascent Therapeutics
|
|
|
|
Craig Johnstone, Value Chain Leader, RA-CVGI, Astrazeneca
|
|
|
|
Troels Koch, Vice Preseident & CTO, Santaris Pharma A/S
|
|
|
|
Steven Ley, BP 1702 Professor of Organic Chemistry, Innovative technology Centre, Department of Chemistry, Cambridge University
|
|
|
|
Jin Li, Director of Computational Chemistry, Astrazeneca
|
|
|
|
Maria Miteva, Senior Scientist, Molécules Thérapeutiques in silico (MTi) Université Paris
|
|
|
|
Jürgen Moll, Director, Dep. Cell Biology, Oncology, Nerviano Medical Sciences
|
|
|
|
John Overington, Team Leader, Chemogenomics, EMBL-European Bioinformatics Institute
|
|
|
|
Michel Pairet, Corporate Senior Vice President, Boehringer Ingelheim
|
|
|
|
Marc Pfister, Executive Director, Discovery Medicine, and Clinical Pharmacology, head of Strategic Modeling and Simulation, Bristol Myers Squibb
|
|
|
|
Birgit Schoeberl, Vice President of Discovery, Merrimack Pharmaceuticals
|
|
|
|
Andreas Sewing, Research Fellow, Director, Primary Pharmacology Unit, Pfizer
|
|
|
|
Jay P. Siegel, Chief Biotechnology Officer, Johnson & Johnson
|
|
|
|
Jens R. Sydor, Head DMPK Ludwigshafen, Abbott GmbH & Co. KG, Germany
|
|
|
|
Nick Terrett, Chief Scientific Officer, Emsemble Discovery Corporation
|
|
|
|
Ian Tomlinson, Senior Vice President, Biopharmaceuticals R&D, GloxoSmithKline
|
|
|
|
Andrew von Eschenbach, Senior Advisor, Greenleaf Health
|
|
|
|
Jeffrey Waring, Associate Research Fellow, Senior Group Leader, Neuroscience Biomarker Abbott
|
|
|
|
Hans Winkler, Senior Director, Global Head Oncology Biomarkers, Ortho Biotech - Johnson & Johnson
|
|
|
|
Paul Wyatt, Director of Drug Discovery, Division of Biological Chemistry & Drug Discovery, College, University of Dundee
|
|
|
|
|
|
|
|
|
|
|
